Huadong Medicine has obtained approvals for three new products at the start of the year, which is nearly half of last year's total.|Quick read announcement.

1. Huadong Medicine announced today that three products have received approval for market entry, while a total of seven products were approved last year; 2. Among them, a hyaluronic acid product for medical aesthetics and a chemical drug for the treatment of ovarian cancer received domestic approval, while a medical instrument for assessing kidney function received approval in the USA; 3. Huadong Medicine believes that the approvals will not have a significant impact on the company's current financial situation and operational results.

cls.cnJan 20 10:31 ET

Opening more new stores but struggling to make a profit, Yixintang Pharmaceutical's net income is expected to drop by over 70% last year | Interpretations

① Yixintang Pharmaceutical expects a Net income decline of 72.7%–81.8% in 2024 compared to the same period last year; ② The company stated that the performance variation is mainly due to the expansion of the company's stores leading to increased Operation costs, as well as some new and relatively new stores being in the initial loss stage.

cls.cnJan 17 09:47 ET

Ginwa Enterprise(Group) Inc. and several senior executives have been criticized for violations of information disclosure regulations! The Chairman has just been placed under investigation | Quick Reading of Announcement.

① Due to violations of information disclosure and the use of raised funds for stock trading, Ginwa Enterprise(Group) Inc. and several senior executives including Director Xing Yajiang have been criticized. Additionally, Xing Yajiang is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws. ② According to Tianyancha, from the end of 2019 to the present, Ginwa Enterprise(Group) Inc. and personnel including Xing Yajiang have received a total of 60 penalties from the Shanghai Stock Exchange, the China Securities Regulatory Commission, and others.

cls.cnJan 14 10:43 ET

After a year, Dong-E-E-Jiao has重订 its incentive plan, with significant adjustments to the stocks grant price and restriction release threshold | Quick announcement summary.

① After a year, Dong-E-E-Jiao has revised its incentive plan, increasing the grant price of the initially granted restricted Stocks from 24.98 yuan per share to 37.22 yuan per share. ② There have also been significant adjustments to the performance assessment requirements at the company level, with the revised net asset return assessment absolute value being higher than before the revision.

cls.cnJan 10 10:49 ET

The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.

① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.

cls.cnJan 6 08:42 ET

Warner Pharmaceutical's centralized procurement plans to win bids for three products, and the proposed bid price for Silver Blade is at a high level compared to similar categories.

① Warner Pharmaceutical's Ginkgo Biloba Blade has been selected for the national Chinese Patent Medicine procurement alliance centralized purchasing (first batch expansion continuation), with the proposed winning price being high for the same category; ② In addition to the price, the final allocation of the procurement volume is also influenced by factors such as the recognition of Medical Institutions, the supply capability of enterprises, and the quality and safety of the products.

cls.cnJan 6 04:44 ET